My take away is accumulate shares at these levels while you can, they will have a drug or two going to the fda in roughly 18 months and generating steady revenue by late 2015 early 2016. Gave cash burn rate at 52 million with 113 on hand, before outsourcing asthma drug. So no secondary for a couple years. Depending on drug sales some approvals hoped for late 2015 and 2016 who knows arry might not need to do any more secondaries at all. Thoughts anyone???
I read the entire transcript and thought they sure have a lot of irons in the fire. Nothing really new, just progress. I thought in the Q&A regarding financing he made mention of the asthma negotiations that could have an impact. We'll have to wait and see.